Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

Abstract

Long-term (≥12 months) treatment with a TNF-α inhibitor, but not methotrexate and ustekinumab, may increase risk for malignancy in patients with psoriasis.